Spinifex Pharmaceuticals is a clinical-stage Australian biotechnology company specialising in the development of products for the treatment of pain.
Phase 2 Program Commences
Spinifex Pharmaceuticals announces the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN).
Latest News & Events
16TH FEBRUARY 2012 Spinifex Wins a BioSpectrum Editor's Choice Award in the Category of 'BioSpectrum Asia-Pacific Emerging ... More
10TH JANUARY 2012 Spinifex presented at the Biotech Showcase 2012 conference in San Francisco ... More
6TH DECEMBER 2011 Appointment of Spinifex Non-Executive Chairman. ... More